REPO4EU Platform Development Update

We are approximately 1.5 years from project completion and six months from a mid-milestone – key points for presenting new versions of the @REPO4EU Platform. At full steam ahead, we are now developing the platform’s interim Beta version, scheduled for launch in Berlin this September. For this, participation in the SC Meeting last week in Brussels was critical and timely. During this meeting, alongside the project coordinator and work package leaders, we reviewed specific task results within the project scope. These research outcomes are highly important as they are integral to the comprehensive platform’s development. The base is taking shape, and we have identified the upcoming components, aiming for seamless teamwork and persistence, as each module contributes to the complete drug-repurposing workflow.

Meanwhile, AI capabilities are expanding, and their demand for resources is growing. Backend architectures and connected systems need continuous adaptation to support increasing computational demands and new functionalities. For this, our role goes beyond development – we continually validate and integrate these technological advancements in order to exploit opportunities and put these results in the service of science. This is quite a high responsibility. We must keep a watchful eye on technology and interpret and integrate results from large-scale partner inputs. Furthermore, we ensure alignment with European data governance and privacy regulations. The EU has recognized the need to accelerate and simplify medical research and certification processes, as the market also sets rules in this area. We keep up the pace, seeing the determination of our partners and positive research results, and our goal remains to integrate these into the REPO4EU state-of-the-art digital ecosystem.

The second event was a TouchBase meeting, where, together with co-partner @Remedi4All project members, we presented the current state of each project and future activities to the European Commission. Egnosis, as the platform architect and integrator of scientific results, presented technological advancements from the Alpha and Beta versions of the REPO4EU platform. Further, as a starting discussion topic, we highlighted connectivity options based on the MCP architecture using the Remedi4All solution. On behalf of the EC, project leader Monica Ensini highlighted the importance of cooperation and common scientific and technological points of connection. This aligns with our presentation, in which we indicated that there are no technological barriers and that we are open to harmonizing two-way, data- and service-based platform features. Our objective is clear: to integrate fragmented research outputs into a functional, scalable and interoperable digital ecosystem for drug repurposing.